TECHNOLOGY THAT PREEMPTS CANCER TM

Our Technology

Through the innovative use of a unique endoscopic brush for tissue acquisition and proprietary Artificial Intelligence (AI) and 3D imaging, CDx Diagnostics is providing patients and doctors with the diagnostic information that they need to make better healthcare decisions in order to help preempt cancer.

Earlier℠

Full-thickness mucosal tissue sampling combined with next generation AI technology empowers clinicians to detect precancerous cells (dysplasia) before they can progress to cancer.

 

01

 

Transepithelial 
Sampling

Unique wide-area tissue collection that captures a complete, full-thickness mucosal specimen down to the muscularis mucosae.

02

 

Artificial Intelligence

Using Deep Learning technology – a clinically trained neural network uses an advanced algorithm to perform a battery of tests to detect precancerous (dysplastic) cells.

Computerized 3D-like cell images are ranked according to degree of atypia to give pathologists a unique 3D-view of esophageal cells.

Deep Learning allows pathologists to find precancer cells similar to trying to find a “needle in a haystack."

03

 

Advanced
3D Imaging

The scanner optically captures the tissue into 20-40 independent "z"-sections and uses CDx-patented technology to merge it into a single synthesized 3-D image that is presented to the pathologist for interpretation.

The reconstructed image presents a unique 3D-like view of the gland, which allows for more accurate diagnosis of dysplasia especially in cases that are atypical and difficult to diagnose.

04

 

Unique Pathology Interface

Areas identified by the neural network as the most likely to be precancerous (dysplasia) are then displayed to the pathologist on a computer screen. The interface allows pathologists to quickly, and accurately identify dysplastic cells that may otherwise have been missed because they are few in number or because they are difficult to diagnose.

Making esophageal cancer a preventable disease.

wats3d card

WATS3D

Included in the Standard of Practice Guidelines for the screening and surveillance of Barrett’s esophagus, WATS3D is our proprietary diagnostic platform for identifying precancerous cells in the esophagus.

Learn more about WATS3d

R&D Pipeline

Advancing science throughout the aerodigestive tract. Learn More

OralCDx

Minimally invasive test for the oral cavity. Learn More

EndoCDx

Minimally invasive test for the larynx and pharynx. Learn More

Case Studies

WATS3D Detects Precancer (Dysplasia) that was Missed in a Patient with Chronic GERD

Gastroesophageal Reflux Disease (GERD) can lead to a condition known as Barrett’s esophagus which results in increased susceptibility for cancer through various stages or precancer termed “dysplasia.” The WATS3D platform allows physicians to more reliably detect dysplasia and provide the necessary treatment and surveillance to prevent cancer from developing.

See more case studies

"You're getting 50 three-micron images which are being stacked on top of each other into a single 3D image which gives you the en face view of the gland - this is really revolutionary."

Nicholas J. Shaheen, MD, MPH
icon-pathology-partnership

Review the strong clinical data behind WATS3D

Learn More

Ready to make your next EGD far more reliable?

Request a Representative

order kits icon

Order Kits

Request additional test kits or patient materials.

Order Now

support icon
Support

Let us help you with questions about our products and services. 

Request Support

lab services Icon

Laboratory Services

Learn about the diagnostic assessments used in evaluating specimens.

Learn More